PharmOptimist schreef op 14 februari 2014 16:33:
Sobi has continued its roll-out of Ruconest® and the drug is now available in the European territory. To date approximately 400-500 angioedema attacks have been treated with Ruconest® since the launch. It is important to remember that every patient can have several attacks per year. Market share for Ruconest® varies significantly between countries. The highest market share during 2012 was reached in Finland (15%) which is expected to grow to a 30% market share during 2013. We expect a continuous increase in patients using Ruconest® during 2013, especially in Central and Eastern European Countries, which will be made possible by the recently obtained pricing and market access approvals in some of these countries. The market access process continues across European markets using the various country specific procedures to obtain reimbursements and to make the product administratively available under the various national and regional healthcare systems.
? To accelerate acceptance of Ruconest® in the key EU markets during the course of 2013, Sobi have recently re-aligned their commercial organisation and have initiated specific in-market actions. After a slow 2012, we therefore now expect a continuous increase in patients using Ruconest® during 2013.